Elutia (NASDAQ:ELUT) Issues Quarterly Earnings Results

Elutia (NASDAQ:ELUT) released its earnings results on Wednesday. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $1.62, FiscalAI reports. The firm had revenue of $3.30 million during the quarter, compared to analysts’ expectations of $3.30 million.

Here are the key takeaways from Elutia’s conference call:

• Elutia submitted NXT-41 to the FDA and expects clearance in the second half of 2026, with the drug‑eluting NXT-41X targeted for clearance toward the end of H1 2027 and a planned commercial launch in H2 2027.
• NXT-41X combines the NXT-41 biologic matrix with rifampin and minocycline to deliver uniform, local antibiotic coverage for roughly 30 days, a design intended to materially reduce postoperative breast‑reconstruction infections (management cited potential ≥~50% reductions versus current ad‑hoc local approaches).
• Management strengthened the balance sheet by selling BioEnvelope to Boston Scientific for $88 million, paying off senior debt, and ending Q4 with $44.4 million in cash plus escrow, which they say funds development through approval and commercialization.
• The company is exploring strategic options for SimpliDerm — a standalone acellular dermal product with reimbursement covering ~100 million lives — which could unlock value but would also remove an operating asset used today.
• Elutia says its Gaithersburg manufacturing facility can support ~$120 million in revenue on one shift, and the company has added commercial leadership and active KOL/VAC engagement to prepare for commercialization.

Elutia Price Performance

Shares of Elutia stock remained flat at $1.09 on Wednesday. 183,194 shares of the stock were exchanged, compared to its average volume of 270,727. The stock has a market cap of $46.54 million, a PE ratio of -1.18 and a beta of 0.65. The firm’s 50-day moving average price is $0.96 and its 200 day moving average price is $0.98. Elutia has a 52-week low of $0.50 and a 52-week high of $3.46.

Insiders Place Their Bets

In other Elutia news, Director Kevin Rakin bought 70,000 shares of the company’s stock in a transaction dated Friday, January 30th. The shares were purchased at an average cost of $1.06 per share, for a total transaction of $74,200.00. Following the transaction, the director directly owned 196,120 shares of the company’s stock, valued at approximately $207,887.20. The trade was a 55.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Matthew Ferguson purchased 60,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was bought at an average cost of $0.53 per share, with a total value of $31,800.00. Following the acquisition, the chief financial officer owned 447,110 shares in the company, valued at $236,968.30. This represents a 15.50% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have bought 255,500 shares of company stock worth $189,605. Insiders own 27.60% of the company’s stock.

Institutional Trading of Elutia

A number of institutional investors have recently made changes to their positions in ELUT. XTX Topco Ltd purchased a new position in Elutia in the second quarter valued at approximately $28,000. Jane Street Group LLC purchased a new stake in shares of Elutia during the first quarter worth approximately $48,000. Virtu Financial LLC purchased a new position in Elutia during the third quarter worth about $26,000. Citadel Advisors LLC acquired a new position in Elutia during the third quarter worth $50,000. Finally, Renaissance Technologies LLC raised its position in Elutia by 64.7% in the fourth quarter. Renaissance Technologies LLC now owns 102,116 shares of the company’s stock worth $71,000 after acquiring an additional 40,123 shares in the last quarter. 74.03% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Elutia in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Elutia presently has a consensus rating of “Hold” and an average target price of $6.00.

About Elutia

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.